Citius Oncology, Inc. (CTOR) — Net Asset Quality Index
Citius Oncology, Inc. (CTOR) has a Net Asset Quality Index of 53.1% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $109.97 Million minus total liabilities of $51.56 Million yields net assets of $58.41 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore how large is Citius Oncology, Inc.'s balance sheet for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Citius Oncology, Inc. Net Asset Quality Index Over Time (2022–2025)
This chart shows how Citius Oncology, Inc.'s Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the index stands at 53.1%, representing net assets of $58.41 Million against total assets of $109.97 Million USD. See CTOR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Citius Oncology, Inc. (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Citius Oncology, Inc. from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Citius Oncology, Inc. market cap and net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 44.4% | $44.87 Million | $100.94 Million | $56.08 Million | ▼ -10.2 pp |
| 2024 | 54.7% | $46.14 Million | $84.37 Million | $38.23 Million | ▲ +1.2 pp |
| 2023 | 53.5% | $25.54 Million | $47.73 Million | $22.20 Million | ▼ -31.5 pp |
| 2022 | 85.0% | $36.27 Million | $42.69 Million | $6.42 Million | — |